Skip to content

DCB Treatment in CTO Guided by IVUS

Drug-coated Balloons Treatment in Chronic Total Occlusion Coronary Artery Disease Guided by Intravascular Ultrasound

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06050096
Enrollment
100
Registered
2023-09-22
Start date
2023-09-01
Completion date
2025-10-01
Last updated
2023-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) coronary artery disease is difficult, the success rate is low, and the incidence of re-occlusion and restenosis is high. With the wide application of imaging technology represented by intravascular ultrasound (IVUS), the success rate of CTO PCI has been significantly improved. Drug-coated balloons (DCB), as a treatment without metal implantation, has lower lumen loss and no significant increase in the rate of revascularization. Through IVUS measurement of vascular lumen after CTO opening, appropriate instruments can be selected for adequate dilation, and appropriate treatment methods can be selected according to different lumen structures. Therefore, the purpose of this study was to evaluate the clinical effect of IVUS-guided DCB therapy on CTO lesions.

Interventions

PROCEDUREPCI

CTO patients treated by DCB

Sponsors

Xuzhou Central Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Over the age of 18, male or female; 2. Patients who meet the diagnostic criteria for coronary heart disease, have clinical symptoms and seek interventional treatment; 3. Coronary angiography confirmed that the blood vessels met the diagnostic criteria of CTO; 4. Sign informed consent and be willing to undergo follow-up for at least 12 months.

Exclusion criteria

1. Patients with severe contrast allergy who cannot tolerate coronary angiography; 2. Patients known allergy to drug balloon coating; 3. Patients who is pregnant or breastfeeding; 4. Bleeding or other diseases, such as digestive tract ulcers, blood system diseases, etc., limit the use of platelet aggregation inhibitors and anticoagulation therapy; 5. Patients with cardiac shock; 6. Patients with a life expectancy of less than 1 year; 7. Other situations deemed unsuitable for inclusion by the researcher.

Design outcomes

Primary

MeasureTime frameDescription
Rate of major adverse cardiovascular events (MACE) in 12 month12 monthcardiovascular death, nonfatal myocardial infarction, and target vessel revascularization

Secondary

MeasureTime frame
Rate of cardiovascular death in 12 month12 month
Rate of nonfatal myocardial infarction in 12 month12 month
Rate of target vessel revascularization in 12 month12 month
Rate of procedure success rate after PCI1 day
Rate of technical success after PCI1 day
Rate of minor bleeding events12 month
Rate of major bleeding events12 month

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026